The U.S. Supreme Court today denied the petition for certiorari brought by CareDX, Inc.in May asking it to review a 2022 decision holding certain claims of its patents directed to detection levels of donor cell-free DNA (cfDNA) in the blood of an organ transplant patient patent ineligible. Justice Bret Kavanaugh would have granted the petition, according to the Order List.
Recent Posts
- Dissecting the USPTO’s Update to Eligibility Guidance for AI Inventions
- Other Barks & Bites for Friday, October 4: Meta Hit with Class Action Copyright Infringement Lawsuit; Industry Leaders Ask for Clarification on Third-Party Litigation; EUIPO Applauds German Court Ruling on Misleading Invoices
- Patently Strategic Podcast: ITC Proofing Portfolios
- USPTO Says Order Terminating More than 3,000 Applications for Fraudulent Signatures is a Warning for Practitioners
- Export Control Requirements When Assigning Chinese Patents and Patent Applications to Foreign Entities